We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+30.73%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$989M
AUM Growth
-$405M
Cap. Flow
-$467M
Cap. Flow %
-47.17%
Top 10 Hldgs %
77.09%
Holding
40
New
5
Increased
2
Reduced
13
Closed
12

Top Buys

Rank Stock Value
1
ARAV
Aravive, Inc. Common Stock
ARAV
+$34.6M
2
DYAX
DYAX CORPORATION
DYAX
+$19.4M
3
AKBA icon
Akebia Therapeutics
AKBA
+$14.4M
4
SCYX icon
SCYNEXIS
SCYX
+$7.35M
5
IMMU
Immunomedics Inc
IMMU
+$3.67M

Top Sells

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$59.6M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$44.4M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$35M
4
ARWR icon
Arrowhead Research
ARWR
+$30.6M
5
PTCT icon
PTC Therapeutics
PTCT
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 60.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TENX icon
26
Tenax Therapeutics
TENX
$393M
$1.29M 0.13%
+10
New +$1.54M
NBIX icon
27
Neurocrine Biosciences
NBIX
$18.2B
$1.02M 0.1%
68,968
-1,100,116
-94% -$15.5M
ATHE
28
CALL
Alterity Therapeutics
ATHE
$80.5M
$227K 0.02%
1,667
– –
ACAD icon
29
Acadia Pharmaceuticals
ACAD
$4.51B
– –
-250,000
Closed -$5.22M
GILD icon
30
PUT
Gilead Sciences
GILD
$165B
– –
-2,400,000
Closed -$170M
LITS
31
Lite Strategy Inc
LITS
$32.4M
– –
-20,417
Closed -$4.54M
MGNX icon
32
MacroGenics
MGNX
$233M
– –
-199,398
Closed -$5.55M
PRTA icon
33
Prothena Corp
PRTA
$448M
– –
-1,554,918
Closed -$59.6M
PTCT icon
34
PTC Therapeutics
PTCT
$6.18B
– –
-981,761
Closed -$25.7M
MRTX
35
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-656,767
Closed -$12.5M
FLXN
36
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-450,000
Closed -$7.4M
TSRO
37
DELISTED
TESARO, Inc.
TSRO
– –
-700,000
Closed -$20.6M
DYAX
38
CALL
DELISTED
DYAX CORPORATION
DYAX
– –
-500,000
Closed -$4.49M
ITMN
39
DELISTED
INTERMUNE INC
ITMN
– –
-300,801
Closed -$10.1M
DSCI
40
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
– –
-1,339,039
Closed -$17M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2014 Portfolio in Review

As of Q2 2014, RA Capital Management held 40 positions worth $989M, down 29% from $1.39B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

RA Capital Management withdrew a net $467M in Q2 2014, closing 12 positions and reducing 13 holdings. Its most notable exit was Prothena Corp, an estimated $59.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 59% a quarter earlier.

Against the trend, RA Capital Management opened a new position in Aravive, Inc. Common Stock worth $50.1M.

  • RA Capital Management's largest Q2 2014 buy was Aravive, Inc. Common Stock: 200,500 shares worth $50.1M.
  • RA Capital Management added most to DYAX CORPORATION in Q2 2014, an estimated $19.4M increase.
  • RA Capital Management's biggest Q2 2014 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $44.4M.
  • RA Capital Management fully exited Prothena Corp in Q2 2014, selling an estimated $59.6M.
  • RA Capital Management's ten largest holdings make up 77% of its $989M portfolio in Q2 2014.
  • RA Capital Management opened 5 new positions and closed 12 in Q2 2014.
  • RA Capital Management's portfolio value fell 29% quarter-over-quarter to $989M.

Based on RA Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.